Weintraub S J, Eschenbacher W L
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0026.
Chest. 1989 Apr;95(4):861-4. doi: 10.1378/chest.95.4.861.
Ten patients with CF who were more than 18 years old, participated in a double-blind, placebo-controlled study evaluating the efficacy of inhaled ipratropium bromide and metaproterenol as bronchodilators. The mean FEV1 of the group improved 17.1 percent after treatment with ipratropium bromide, 12.5 percent after metaproterenol treatment, and 16.6 percent after treatment with both of these medications together. There was no significant difference between these responses and patients who responded to one treatment tended to respond to the others. The side effects with these medications were minimal. When compared with patients in previous studies, our patients, who were much older as a group, demonstrated a greater degree of bronchodilation with ipratropium bromide and metaproterenol, as well as a greater degree of bronchoconstriction with placebo.
10名年龄超过18岁的囊性纤维化患者参与了一项双盲、安慰剂对照研究，该研究评估了吸入用异丙托溴铵和间羟异丙肾上腺素作为支气管扩张剂的疗效。使用异丙托溴铵治疗后，该组患者的平均第一秒用力呼气量（FEV1）提高了17.1%，使用间羟异丙肾上腺素治疗后提高了12.5%，两种药物联合使用后提高了16.6%。这些反应与对一种治疗有反应的患者对其他治疗也有反应的情况之间没有显著差异。这些药物的副作用很小。与之前研究中的患者相比，我们这群年龄大得多的患者使用异丙托溴铵和间羟异丙肾上腺素后表现出更大程度的支气管扩张，使用安慰剂后则表现出更大程度的支气管收缩。
